Dietmar Hopp (Malte Ossowski/SVEN SIMON/picture-alliance/dpa/AP Images)

Bil­lion­aire Di­et­mar Hopp steers his se­cre­tive Covid-19 biotech play­er to Nas­daq fol­low­ing ma­jor pact with GSK

One of the most se­cre­tive biotech can­di­dates to lead the de­vel­op­ment of a new mR­NA vac­cine to fight Covid-19 just filed their IPO pa­pers for Nas­daq.

Cure­Vac, which has been slow to re­veal de­tails about its bid to de­vel­op a new Covid-19 vac­cine, out­lined a slate of al­liances — in­clud­ing the news that its $1.8 bil­lion deal with Eli Lil­ly is ka­put — with a host of glob­al play­ers in­volved in its bid to cut to the front of the pack in mR­NA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.